Effects of VitabridC¹² on Skin Inflammation

Abstract

Background

VitabridC¹² is newly developed and composed of vitamin C and Vitabrid (lamellar, hydrated zinc oxide).

Objective

In this study, we aimed to investigate the effects of VitabridC¹² on psoriasis and atopic dermatitis.

Methods

Mice with imiquimod-induced psoriasis or Dermatophagoides farinae-induced atopic dermatitis were applied with VitabridC¹². The effects of VitabridC¹² were evaluated by clinical features, histology, and immunologic features by examining cytokines and chemokines.

Results

In psoriasis model, VitabridC¹² decreased epidermal thickness and reduced inflammatory cell infiltration. In atopic dermatitis model, VitabridC¹² decreased dermal infiltration of inflammatory cells, epidermal hyperplasia, and hyperkeratosis. VitabridC¹² reduced the expression levels of proinflammatory mediators such as interleukin (IL)-1β, IL-6, IL-8, IL-17A, IL-22, tumor necrosis factor-α, CXCL1, CCL17, and CCL20 as well as COX-2 in imiquimod-induced psoriatic skin lesions. Likewise, VitabridC¹² reduced the expression levels of IL-4, IL-5, IL-13, thymic stromal lymphopoietin, and CCL4 in D. farinae-induced skin lesions, and decreased the serum immunoglobulin E level in the atopic dermatitis mouse model. Particularly, the VitabridC¹²-treated mice showed downregulated expressions of mitogen-activated protein kinase (MAPK), including extracellular signal-regulated kinase (ERK), p38, and MAPK/ERK kinase, as well as inhibited phosphorylation of nuclear factor-κB p65.

Conclusion

Taken together, these findings indicate that VitabridC¹² exhibits anti-inflammatory activities and is a promising candidate as a treatment option for psoriasis or atopic dermatitis.

INTRODUCTION

Psoriasis and atopic dermatitis (AD) are chronic relapsing skin diseases characterized by dryness of the skin due to the impairment of the skin-barrier function¹. Although the etiologies of both diseases have not been fully understood yet, studies on their pathogenesis have revealed that both are highly associated with the dysregulation of the immune system, mainly involving T cells. Psoriasis affects 2% to 3% of the whole population². Its cause remains unknown even though genetic, environmental, and immunologic factors are known to be associated with the pathogenesis of psoriasis³. AD is characterized by severe pruritus and eczema. It has a prevalence of 10% to 20% in industrialized countries⁴,⁵. AD is highly associated with immune system imbalance, especially with T-helper (Th)2 immune responses⁶.

Vitamin C, also known as ascorbic acid, is a water-soluble ingredient found in fruits and vegetables. It has been traditionally utilized as an anti-oxidant and anti-aging agent⁷. However, vitamin C is unstable, easily oxidized, and decomposed into biologically inactive compounds⁸. In addition, intact vitamin C cannot easily penetrate the skin barrier due to its hydrophilic property. Therefore, a safer and stable delivery system for vitamin C needs to be developed by utilizing platforms such as microcapsules, nanospheres, or liposomes⁹. Choy et al.¹⁰ reported that unstable biological molecules can be successfully stabilized and effectively delivered to target tissues when they are encapsulated in a layered inorganic matrix of Vitabrid. Vitabrid is composed of the lamellar structure of hydrated zinc oxide (ZnO), which has been used in the management of many skin diseases because of its antioxidant, anti-inflammatory, and anti-bacterial effect¹¹. Particularly, VitabridC¹² is vitamin C incorporated into Vitabrid through the new technology of putting vitamin C in the layered complex of mineral carrier. It is composed of approximately 40-µm powdered particles. It formed into a nanoporous shell structure, which is coated with glyceryl monostearate. Glyceryl monostearate, emulsifier, can prevent the aggregation of vitamin C particles and increase skin's affinity values by hydrophobic modification of its surface.

The molecular mechanisms and therapeutic effect of VitabridC¹², however, have not been clearly understood. In this study, we aimed to investigate the effect of VitabridC¹² on skin diseases in psoriasis and AD mouse models by using imiquimod and Dermatophagoides farinae body (Dfb) extracts, respectively. Our results demonstrate that topical application of VitabridC¹² significantly reduced skin lesions. The therapeutic action and effect of VitabridC¹² on chronic inflammatory skin diseases was demonstrated in this study.

MATERIALS AND METHODS

All animal care was performed in accordance with the Guide for the Care and Use of Laboratory Animals (Washington DC, USA) and was approved by the Animal Care and Use Committee of The Catholic University of Korea (2014-0090-01).

Mice and materials

Female C57BL/6 and NC/Nga mice were purchased from Charles River Japan (Yokohama, Japan). These mice were all housed under conditions of controlled temperature (20℃~26℃), humidity (30%~70%), and lighting (lights on from 8 AM to 8 PM). Mice at 7 to 11 weeks of age were used for all the experiments and maintained in a specific pathogen-free barrier facility. VitabridC¹² and Vitabrid were obtained from Hyundai IBT Ltd. (Seoul, Korea).

Establishment of imiquimod-induced psoriasiform dermatitis-like mouse models

Mice at 8 weeks of age daily received topical application of 62.5 mg of commercially available imiquimod cream (5%) (Aldara; 3M Pharmaceuticals, St. Paul, MN, USA) for 6 consecutive days. Control mice were daily treated similarly with a control vehicle cream (Vaseline Lanette cream; Fagron, Rotterdam, The Netherlands) for 6 consecutive days. VitabridC¹² or Vitabrid were daily applied into the mouse back, followed 12 hours later by topical treatment with imiquimod. We performed experiments with five mice in each group every experiment. We repeated this experiment three times. Four experimental groups were as follows: control vehicle group (Vaseline was applied twice a day), imiquimod group (imiquimod and Vaseline were applied daily with 12-hour interval), Vitabrid group (imiquimod and Vitabrid were applied daily with 12-hour interval), and VitabridC¹² group (imiquimod and VitabridC¹² were applied daily with 12-hour interval).

Preparation of Dfb ointment and induction of AD-like mouse models

Dfb ointment, which is mixture of hydrophilic penetration and 5 mg of Dfb extract per gram hydrophilic petrolatum, was purchased from Biostir Inc. (Kobe, Japan). Hair on the upper back of the mice was removed with a clipper and a shaver 1 day before the experiment. Elicitation was performed by topical application of 100-mg Dfb ointment or ointment base (hydrophilic petrolatum) on the shaved dorsal skin and both surfaces of each ear. Barrier disruption was achieved by applying 150 µl of 4% sodium dodecyl sulfate on the shaved dorsal skin and both surfaces of each ear 3 hours before the Dfb ointment application. These procedures were repeated twice a week. We performed experiments with five mice in each group every experiment and repeated this experiment three times. Four experimental groups were as follows: control vehicle group (hydrophilic petrolatum was applied twice a week), Dfb group (Dfb ointment was applied twice a week), Vitabrid group (Dfb ointment was applied twice a week and Vitabrid was applied daily for 6 consecutive days. If Dfb ointment and Vitabrid needed to be applied on the same day, there was at least 12 hours' interval between Dfb ointment and Vitabrid treatments.), and Vitabrid C¹² group (Dfb ointment was applied twice a week and Vitabrid C¹² was applied daily for 6 consecutive days. Similar to Vitabrid, if Dfb ointment and VitabridC¹² needed to be applied on the same day, there was at least 12 hours' interval between Dfb ointment and VitabridC¹² treatments.).

Histological analysis

Skin lesions taken from the imiquimod- and Dfb-treated mice were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 24 hours, washed with tap water, dehydrated with grade ethanol, and then embedded in paraffin. The paraffin blocks were cut in 4-µm-thick sections, mounted on glass slides, dewaxed, rehydrated with grade ethanol, and then stained with hematoxylin-eosin (H&E). Analysis was performed by using a microscope. All histological studies were performed in a blinded manner by two experienced dermatopathologists.

RNA isolation and quantitative real-time polymerase chain reaction

Total RNA was isolated from mouse skin by using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The first cDNA strand was synthesized from 1-µg total RNA by using a QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany). The QuantiTect primer assay (Qiagen) was used as primer sets for interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-8, IL-13, IL-17A, IL-22, tumor necrosis factor (TNF)-α, CXCL1, CCL4, CCL17, CCL20, and thymic stromal lymphopoietin (TSLP). Glyceraldehyde-3-phosphate dehydrogenase messenger RNA was used as an endogenous control. Polymerase chain reaction (PCR) was performed by using Rotor-Gene 6000 (Corbett, Mortlake, Australia) and QuantiTect SYBR Green PCR Kit (Qiagen). The amplification program consisted of 1 cycle at 95℃ for 10 minutes, followed by 35 cycles at 95℃ for 20 seconds, 55℃ for 20 seconds, and 72℃ for 20 seconds.

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting analysis

Samples were separated by SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Pall Corp., Port Washington, NY, USA). Membranes were blocked for 1 hour in a blocking buffer (5% skim milk in 25 mM Tris-HCl [pH 8.0], 150 mM NaCl, and 0.1% Tween 20) and incubated overnight at 4℃ with specific primary antibodies for target signaling. Blots were washed and incubated with horseradish peroxidase-conjugated secondary antibodies for 2 hours at room temperature, and the signals were detected by using radiography after reaction with an enhanced chemiluminescence detection kit (iNtRON Biotechnology, Seongnam, Korea).

Enzyme-linked immunosorbent assay

The amounts of total immunoglobulin E (IgE) in sera were determined by using sandwich enzyme-linked immunosorbent assay as previously described¹². In brief, 96-well plates were coated with monoclonal anti-mouse IgE overnight at 4℃ and then further treated with 2% (w/v) bovine serum albumin dissolved in PBS containing 0.05% Tween 20 (PBS-T) for 2 hours at room temperature to block nonspecific binding. Next, serum samples were serially diluted in duplicated wells and incubated for 1 hour at room temperature. After 3 rinses with PBS-T, biotin-conjugated rat anti-mouse IgE Ab (LO-ME-2) was added to the wells, followed by the addition of streptavidin-peroxidase (Seikagaku Corp., Tokyo, Japan). After 3 rinses, the plates were developed by using a substrate solution containing 0.04% O-phenylenediamine dissolved in phosphate citrate buffer (pH 5.0). The reactions were terminated by the addition of sulfuric acid. The absorbance was read by using a microplate reader at 490 nm, and the amount of IgE isotype was calculated by comparison with the mouse IgE standard (Pharmingen, San Diego, CA, USA).

Statistical analysis

These results are representative of 3 independent experiments (n=5 for each group). Each data represents the mean value±standard error of three independent experiments. Statistical analyses were conducted with IBM SPSS Statistics ver. 19.0 for Windows (IBM Co., Armonk, NY, USA). Statistical analysis between multiple groups was performed using the one-way analysis of variance (ANOVA) (Kruskal-Wallis test) followed by Dunn's Multiple Comparison test. p-values <0.05 were considered statistically significant.

RESULTS

VitabridC¹² alleviated imiquimod-induced psoriasiform inflammation in the mouse model

To examine the effects of VitabridC¹² on psoriasis, psoriasiform dermatitis was induced on the back of the mice by the application of imiquimod daily for 6 days. Unlike the control group, the imiquimod group had induced skin swelling, which is the first hallmark of local skin inflammation (Fig. 1A). In addition, histopathological evaluation of the skin showed epidermal hyperplasia (acanthosis), hyperkeratosis, and increased dermal inflammatory cell infiltration in the imiquimod group compared to the control group (Fig. 1B). The thickness of the epidermis and dermis, and inflammatory cell infiltration significantly decreased in the Vitabrid or VitabridC¹² group compared to the imiquimod group (Fig. 1C). Notably, the VitabridC¹² group showed less inflammation than the Vitabrid group in the dermal thickness (p<0.05).

Fig. 1. Effect of VitabridC¹² on imiquimod-induced psoriasiform inflammation in BALB/c mice. (A) Skin lesions of psoriasiform inflammation. Images of skin lesions were taken in the 8th week. (B) H&E stained skin recovered in the 8th weeks (×100). VitabridC¹² reduced acanthosis and inflammatory cell infiltration in the imiquimod skin lesions. (C) Epidermis thickness and dermal edema were evaluated at the 8th week. Vitabrid and VitabridC¹² decreased skin thickness. Representative clinical presentations of the mice from the control group, imiquimod group, Vitabrid group, and VitabridC¹² group are shown. These results are representative of 3 independent experiments (n=5 for each group). Each data represents the mean value±standard error of three independent experiments. ^*p<0.05.

VitabridC¹² alleviated the Dfb-induced AD-like inflammation in the mouse model

To examine the effects of Vitabrid C¹² on the AD murine model, Dfb ointment was applied on the back of Nc/Nga mice twice for 3 weeks. Changes in the skin thickness after 3 weeks are shown in Fig. 2. Apparent acanthosis and edematous skin swelling occurred after the application of Dfb ointment in NC/Nga mice compared to the control group. Histological examination revealed an increased inflammatory response, including dense dermal infiltration of leukocytes, epidermal hyperplasia, and hyperkeratosis in the Dfb ointment-treated mice skin. As we expected, VitabridC¹² was effective in decreasing these inflammatory responses (Fig. 2B). In the VitabridC¹² group, the thicknesses of the epidermis markedly decreased, compared to the Dfb group (p<0.05, Fig. 2C). Interestingly, in toluidine blue staining, the mast cells more significantly decreased in the VitabridC¹² group than in the Dfb control group (p<0.05, Fig. 3).

Fig. 2. VitabridC¹² alleviated the Dermatophagoides farinae body (Dfb)-induced atopic dermatitis (AD)-like inflammation in the mouse model. (A) Skin lesions of AD-like skin inflammation. Images of skin lesions were taken in the 3rd week. (B) H&E stained skin recovered in the 3 weeks (×100). (C) Epidermal and dermal thickness were evaluated. VitabridC¹² markedly decreased skin thickness; VitabridC¹² reduced acanthosis and inflammatory cell infiltration in the AD-like skin lesions. Representative clinical presentations of the mice from the control group, Dfb group, Vitabrid group, and VitabridC¹² group are shown. Data represent mean values±standard error (n=5). ^*p<0.05. The data shown are representative of three independent experiments.

Fig. 3. The number of mast cells in the dorsal skin in Nc/Nga mice. (A) Histological assessment was performed by toluidine blue staining (×100). Purple colored cells were counted. (B) The number of mast cells in atopic dermatitis-like skin lesions and VitabridC¹²-treated skin lesions were determined. Purple cells (arrows) were counted. The number of cells at ×400 magnification was counted for each section using 3 randomly selected fields. Data represent mean values±standard error (n=5). ^*p<0.05. The data shown are representative of three independent experiments.

VitabridC¹² suppressed the expressions of the inflammatory mediators in psoriasiform dermatitis

VitabridC¹² was found to be effective in inhibiting the development of imiquimod-induced cutaneous inflammation in mice skin. Next, we performed quantitative real-time PCR analysis in mice skin to examine the mRNA expression levels of proinflammatory mediators. Similar to the histological changes, real-time PCR analysis revealed that the mRNA expression levels of proinflammatory cytokines such as IL-1β, IL-6, IL-8, TNF-α, IL-17A, and IL-22 increased in the imiquimod-treated mouse ears, whereas these mRNA expression levels decreased significantly in the VitabridC¹² group (Fig. 4). VitabridC¹² inhibited the mRNA expressions of IL-17A and IL-22, the signature cytokines of the Th17 cell lineage. Furthermore, treatment with VitabridC¹² significantly hindered the mRNA expression levels of the other inflammatory chemokines such as CXCL1, CCL17, and CCL20, which are highly elevated in psoriasis¹³,¹⁴,¹⁵.

Fig. 4. VitabridC¹² inhibited imiquimod-induced inflammatory responses in the mouse skin. Total RNA was isolated from the skin lesions of imiquimod-induced mice, and quantitative real-time polymerase chain reaction was performed to examine psoriasis-specific cytokines. VitabridC¹² decreased the mRNA expression levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8, IL-17A, IL-22, CXCL1, CCL20, and CCL17, and thereby ameliorated imiquimod-induced psoriasiform inflammation in the skin lesion. Data represent mean values±standard error (n=5). ^*p<0.05. The data shown are representative of three independent experiments.

VitabridC¹² suppressed the expressions of the inflammatory mediators and IgE in the AD mouse model

We also investigated whether VitabridC¹² downregulated the production of cytokines and chemokines in the Dfb-induced skin lesions of the NC/Nga mice. Quantitative real-time PCR analysis revealed that the mRNA expression levels of T cell-specific cytokines such as IL-4, IL-5, and IL-13 increased in the Dfb-treated mice ears, whereas VitabridC¹² inhibited these mRNA expression levels. Compared to Dfb group, VitabridC¹² is significantly inhibiting the mRNA expressions of TSLP, IL-4, IL-13 and CCL4 (p<0.05, Fig. 5A). Furthermore, VitabridC¹² significantly downregulated the mRNA expression of TSLP, IL-4, and CCL4 more effectively than Vitabrid (p<0.05, Fig. 5A).

Fig. 5. VitabridC¹² inhibited Dermatophagoides farinae body (Dfb)-induced inflammatory responses in the Nc/Nga mouse skin. (A) Total RNA was isolated from the skin lesions of Dfb-treated mice, and quantitative real-time polymerase chain reaction was performed to examine atopic dermatitis-specific cytokines. VitabridC¹² decreased the mRNA expression levels of thymic stromal lymphopoietin (TSLP), CCL4, interleukin (IL)-4, IL-5, and IL-13. Data represent mean values±standard error (SE) (n=5). ^*p<0.05. The data shown are representative of three independent experiments. (B) Immunoglobulin E (IgE) was quantified by performing an enzyme-linked immunosorbent assay. Representative clinical presentations of the mice from the control group, Dfb group, Vitabrid group, and VitabridC¹² group are shown. Data represent mean values±SE (n=5). ^*p<0.05. The data shown are representative of three independent experiments.

Then, we tried to investigate whether VitabridC¹² could modulate the serum IgE levels in the Dfb-induced mice. The total IgE levels in the sera obtained from the mice are shown in Fig. 5B. The IgE levels increased in the Dfb-treated mice. The VitabridC¹²-treated mice displayed relatively lower levels of total serum IgE than Vitabrid-treated mice (p<0.05).

VitabridC¹² downregulated the MAPK and NF-κB signaling pathways

In addition, we examined whether VitabridC¹² could inhibit mitogen-activated protein kinase (MAPK) signaling pathways that play key roles in inflammatory signaling in mammalian cells¹⁶,¹⁷. Nuclear factor (NF)-κB p65 is the active subunit of NF-κB. Overactivation of NF-κB signaling leads to inflammatory disorders¹⁸. COX-2 is an inducible enzyme that converts arachidonic acid into prostaglandins and is involved in various inflammatory diseases¹⁹. VitabridC¹² inhibited phosphorylation of MAPK/ERK kinase (MEK), extracellular signal-regulated kinase (ERK), and p38 in the imiquimod-treated mice. Moreover, VitabridC¹² hindered phosphorylation of NF-κB p65 and reduced the expression levels of COX-2 in the imiquimod-treated mice (Fig. 6). Thus, we might speculate that VitabridC¹² could downregulate cutaneous inflammation via inhibition of the MAPK kinase and NF-κB pathways.

Fig. 6. VitabridC¹² inhibited cutaneous inflammation via the nuclear factor-κB signaling pathway. Protein extracts were prepared, and western blot analysis was performed with antibodies specific for the molecules indicated. pERK, p-p38, pMEK, p-p65, and COX-2 expression levels increased in psoriatic skin. The protein levels of pERK (44, 48 kDa), p-p38 (38 kDa), pMEK (44, 45 kDa), p-p65 (65 kDa), and COX-2 (75 kDa) decreased after treatment with VitabridC¹². ERK: extracellular signal-regulated kinase, MEK: mitogen-activated protein kinase/ERK kinase, GAPDH: glyceraldehyde-3-phosphate dehydrogenase.

DISCUSSION

VitabridC¹² is a novel compound composed of a glyceryl monostearate -coated, layered vitamin C-Vitabrid complex. Vitamin C has long been regarded as a potent antioxidant agent²⁰. However, because of its instability and the difficulty in delivering it into the dermis, many studies have been conducted to find stable compounds of and new delivery systems for vitamin C. Vitabrid is a hydrated ZnO in the lamellar structure, which causes minimal skin irritation¹⁰. ZnO also helps the skin restore disturbed skin-barrier function and enhance wound healing with its antimicrobial effects²¹,²². It has also an anti-inflammatory effect by reducing neutrophil chemotaxis in psoriatic patients²³. Because VitabridC¹² is coated with hydrophobic glyceryl monostearate, the innovative substance penetrates into the skin more efficaciously than other vitamin compounds. Whereas vitamin C can be easily destroyed within 3 to 4 hours of exposure to air, VitabridC¹² consistently releases vitamin C for longer than 12 hours. Furthermore, as VitabridC¹² exchanges ions with perspiration (NaCl) from sweat glands and CO₂ from the air, it can help in the absorption of vitamin C in the deep skin layer.

However, the biological and pharmacological activities of VitabridC¹² are not well understood, specifically how it works in skin inflammatory diseases. Therefore, we investigated whether VitabridC¹² could modulate skin inflammation in psoriasis and AD mouse models by using imiquimod and Dfb ointment, respectively. Topical application of VitabridC¹² suppressed imiquimod-induced skin thickness and dermal inflammatory cell infiltration. The results suggested that treatment with VitabridC¹² could exert significant anti-inflammatory effects on cutaneous inflammation. In addition, Vitabrid C¹² significantly suppressed the expressions of proinflammatory mediators, including TNF-α, IL-1β, IL-6, IL-8, IL-17A, IL-22, CXCL1, CCL17, CCL20, and COX-2, which were elevated in psoriatic skin lesions²⁴,²⁵,²⁶,²⁷,²⁸,²⁹,³⁰,³¹.

Previous studies showed that in psoriatic skin lesions, the expression levels of ERK, JNK, and p38 were increased in the MAPK pathway¹⁶,³²,³³. Therefore, we investigated the MAPK and NF-κB signaling pathways³⁴,³⁵,³⁶,³⁷,³⁸. Our study demonstrated that VitabridC¹² could reduce the activities of p38, ERK, and MEK. While multiple signaling pathways, including NF-κB, are dysregulated in psoriatic epidermis³⁹, VitabridC¹² treatment reduced the phosphorylation of p65, a component of the NF-κB pathway. Our results showed that the therapeutic effect of VitabridC¹² on the expression and production of proinflammatory mediators is associated with the inhibition of the MAPK kinase and NF-κB signaling pathways.

To study the effect of VitabridC¹² on AD, we induced AD in NC/Nga mice by applying Dfb ointment. Our results showed that VitabridC¹² efficiently suppressed the infiltration of inflammatory cells, including mast cells, and decreased the levels of the Th2 subset cytokines. Elevated serum IgE level is observed in most AD patients⁴⁰. VitabridC¹² also reduced the serum IgE level in the NC/Nga mice. AD keratinocytes secrete TSLP, which activates dendritic cells to prime naive T cells to produce IL-4 and IL-13⁴¹. In chronic AD, IL-5 is involved in eosinophil development and survival⁴². CCL4, also known as macrophage inflammatory protein 1β, is a CC chemokine with specificity for CCR5 receptors⁴³. Serum CCL4 level is significantly elevated in patients with AD. Topical application of VitabridC¹² significantly reduced AD symptoms and the levels of AD-related markers, including IL-4, IL-5, IL-13, CCL4, and TSLP. Sivaranjani et al.⁴⁴ suggested that antioxidants such as Vitamin C may be helpful in the treatment of AD. We suggested that stable Vitamin C with Vitabrid may have synergic effect to AD.

The results of this study show that VitabridC¹² reduce the cutaneous inflammation in psoriasis and AD model mice via modulating the complex network of cytokine-mediated signaling cascades. Moreover, VitabridC¹² effectively inhibited diverse signaling pathways, including MAPK and NF-κB signaling. These results also propose that VitabridC¹², a stable form of vitamin C with ZnO in the lamellar structure, has an enhanced ability to control skin inflammation. In conclusion, we propose the use of VitabridC¹² as an effective treatment option for psoriasis and AD.

In summary, we observed that topical application of VitabridC¹² decreased the number of inflammatory cells and the expression levels of diverse markers, thus reducing psoriasis or AD-like symptoms in the mice in this study. The effect of VitabridC¹² might be associated with NF-κB and MAPK signaling pathways. Collectively, our results suggest that Vitabrid C¹² is a promising candidate as a treatment option for management of psoriasis and AD.